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A commentary on
Long-term mortality after recombinant 
growth hormone treatment for isolated 
growth hormone deficiency or childhood 
short stature: preliminary report of the 
French SAGhE study
by Carel, J. C., Ecosse, E., Landier, F., 
Meguellati-Hakkas, D., Kaguelidou, F., Rey, 
G., and Coste, J. (2012). J. Clin. Endocrinol. 
Metab. 97, 416–425.
Substantial experimental evidence supports 
the involvement of growth hormone (GH) 
and, especially, its main effector insulin-like 
growth factor-I (IGF-I) in the development, 
growth, and dissemination of several types 
of cancer (Cianfarani and Rossi, 1997; Holly 
et al., 1999, Renehan et al., 2004; Clayton 
et al., 2011). However, although the data 
from in vitro and in vivo studies are robust, 
the evidence in humans is weak (Clayton 
et al., 2011).
Growth hormone extracted from human 
pituitaries (hGH) became available for ther-
apy of GH deficient children in early 1960s. 
In 1985, following the reports of an associa-
tion of this treatment with the occurrence 
of Creutzeldt–Jakob disease, human GH was 
banned and replaced by recombinant hGH 
(rhGH). Since then, due to the unlimited 
supply of this molecule, the indications for 
rhGH have greatly expanded worldwide, 
now including childhood and adult GH 
deficiency, Turner syndrome, chronic renal 
failure, small for gestational age (SGA), 
Prader–Willi syndrome, Noonan syndrome, 
SHOX deficiency, idiopathic short stature 
(ISS), and AIDS wasting. Despite a so long 
time of use in so many different clinical 
conditions, rhGH has rarely been associated 
with the occurrence of serious side effects. 
However, longitudinal studies aimed at eval-
uating the health of adult subjects treated 
with rhGH during childhood are few and 
often not independent of Pharmaceutical 
Companies. Nevertheless, an association of 
hGH or rhGH treatment with a higher inci-
dence of cancer (Swerdlow et al., 2002) and 
type 2 diabetes (Cutfield et al., 2000; Child 
et al., 2011) has been reported.
The recent publication of two stud-
ies stemming from SAGhE (Safety and 
Appropriateness of GH treatments in 
Europe) European consortium, which was 
started in 2009 and includes eight countries 
(France, Sweden, Belgium, the Netherlands, 
Switzerland, Germany, United Kingdom, 
and Italy), has generated confusion and 
controversy rather than shedding light 
on this delicate matter (Carel et al., 2012; 
Sävendahl et al., 2012). The French study 
reported a significant increase in both all-
cause mortality and specific mortality for 
bone tumors or cerebral hemorrhage in a 
cohort of about 6500 young adult subjects 
treated with rhGH during childhood for 
GH deficiency, SGA, or ISS (Table 1). On 
the basis of these findings, in 2010 the EMA’s 
Committee for Medicinal Products for 
Human Use (CHMP) launched a warning 
aimed at narrowing the dose range used in 
the different indications approved in Europe 
and started a review of all  available data to 
Long-term safety of growth hormone therapy: still a 
controversial issue
Stefano Cianfarani*
Department of Systems Medicine, Tor Vergata University and Molecular Endocrinology Unit-Bambino Gesù Children’s Hospital, Rome, Italy
*Correspondence: stefano.cianfarani@uniroma2.it
Edited by:
Ze’Ev Hochberg, Technion-Israel Institute of Technology, Israel
Table 1 | Preliminary data reported from SAGhE (Safety and Appropriateness of Growth hormone 
treatments in Europe) project.
France Neoplasms Observed Expected SMR (95% CI)
 All-cause 7 6.89 1.02 (0.41–2.09)
 Malignant neoplasm 3 0.60 5.00 (1.01–14.61) 
 of bone and articular 
 cartilage
 Cerebrovascular 4 0.76 5.29 (1.42–13.55) 
 diseases
Sweden, The Netherlands, Belgium Cause of death Number of deaths
 Traffic accident 5
 Accident 2
 Suicide 4
 Homicide 1
 Poisoning 4
 Pneumonia 1
 Other Endocrine Dysfunction 1
 Primary cardiomyopathy 1
 Immune deficiency 1
 Coagulation defect 1
 Cancer 0
 Cerebrovascular diseases 0 
Data are expressed in Standardized Mortality Ratio (SMR) for France, and absolute number of deaths for 
Sweden, The Netherlands and Belgium.
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cies, pharmaceutical companies, patients, 
and their families), to invest resources and 
expertise in setting up an international task 
force aimed at addressing this still contro-
versial issue (Rosenfeld et al., 2012).
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assess the risk-benefit balance. In contrast 
to the French data, the other study involv-
ing patients from Sweden, The Netherlands, 
and Belgium, reported not a single case of 
death from cancer or cerebrovascular dis-
ease in about 2500 subjects with the same 
diagnoses (Table 1).
Both studies show a series of potential 
biases such as the relative small sample size, 
the low event rate, the lack of an untreated 
control group available for comparison, and 
the lack of reference data in the age groups 
including height. In addition, it is hard to 
explain the opposite results. Differences 
in genetics, environment, or, more simply, 
confounding factors might account for 
the discrepancy between the two SAGhE 
sub-studies.
Due to the large number of individuals 
treated with rhGH nowadays, it is urgent to 
obtain definitive data on the safety of this 
therapy. The SAGhE project is due to finish 
in November 2012 and the analysis of the 
whole cohort (about 25,000 subjects) will 
provide more complete and robust data. 
These two preliminary SAGhE reports have 
undoubtedly the merit to stress the impor-
tance to replicate these surveys in different 
contexts, and to provide the methodological 
background for a joint effort involving all the 
stakeholders (physicians, regulatory agen-
Frontiers in Endocrinology | Pediatric Endocrinology  September 2012 | Volume 3 | Article 115 | 2
Cianfarani Growth hormone safety
